TY - JOUR
KW - General Medicine
AU - Bourne R
AU - Steinmetz JD
AU - Flaxman S
AU - Briant PS
AU - Taylor HR
AU - Resnikoff S
AU - Casson RJ
AU - Abdoli A
AU - Abu-Gharbieh E
AU - Afshin A
AU - Ahmadieh H
AU - Akalu Y
AU - Alamneh AA
AU - Alemayehu W
AU - Alfaar AS
AU - Alipour V
AU - Anbesu EW
AU - Androudi S
AU - Arabloo J
AU - Arditi A
AU - Asaad M
AU - Bagli E
AU - Baig AA
AU - Bärnighausen TW
AU - Battaglia Parodi M
AU - Bhagavathula AS
AU - Bhardwaj N
AU - Bhardwaj P
AU - Bhattacharyya K
AU - Bijani A
AU - Bikbov M
AU - Bottone M
AU - Braithwaite T
AU - Bron AM
AU - Butt ZA
AU - Cheng C
AU - Chu D
AU - Cicinelli MV
AU - Coelho JM
AU - Dagnew B
AU - Dai X
AU - Dana R
AU - Dandona L
AU - Dandona R
AU - Del Monte MA
AU - Deva JP
AU - Diaz D
AU - Djalalinia S
AU - Dreer LE
AU - Ehrlich JR
AU - Ellwein LB
AU - Emamian MH
AU - Fernandes AG
AU - Fischer F
AU - Friedman DS
AU - Furtado JM
AU - Gaidhane AM
AU - Gaidhane S
AU - Gazzard G
AU - Gebremichael B
AU - George R
AU - Ghashghaee A
AU - Golechha M
AU - Hamidi S
AU - Hammond BR
AU - Hartnett MER
AU - Hartono RK
AU - Hay SI
AU - Heidari G
AU - Ho HC
AU - Hoang CL
AU - Househ M
AU - Ibitoye SE
AU - Ilic IM
AU - Ilic MD
AU - Ingram AD
AU - Irvani SSN
AU - Jha R
AU - Kahloun R
AU - Kandel H
AU - Kasa AS
AU - Kempen JH
AU - Keramati M
AU - Khairallah M
AU - Khan EA
AU - Khanna RC
AU - Khatib MN
AU - Kim JE
AU - Kim YJ
AU - Kisa S
AU - Kisa A
AU - Koyanagi A
AU - Kurmi OP
AU - Lansingh VC
AU - Leasher JL
AU - Leveziel N
AU - Limburg H
AU - Majdan M
AU - Manafi N
AU - Mansouri K
AU - McAlinden C
AU - Mohammadi SF
AU - Mohammadian-Hafshejani A
AU - Mohammadpourhodki R
AU - Mokdad AH
AU - Moosavi D
AU - Morse AR
AU - Naderi M
AU - Naidoo KS
AU - Nangia V
AU - Nguyen CT
AU - Nguyen HLT
AU - Ogundimu K
AU - Olagunju AT
AU - Ostroff SM
AU - Panda-Jonas S
AU - Pesudovs K
AU - Peto T
AU - Quazi Syed Z
AU - Rahman MHU
AU - Ramulu PY
AU - Rawaf S
AU - Rawaf DL
AU - Reinig N
AU - Robin AL
AU - Rossetti L
AU - Safi S
AU - Sahebkar A
AU - Samy AM
AU - Saxena D
AU - Serle JB
AU - Shaikh MA
AU - Shen TT
AU - Shibuya K
AU - Shin JI
AU - Silva JC
AU - Silvester A
AU - Singh JA
AU - Singhal D
AU - Sitorus RS
AU - Skiadaresi E
AU - Skirbekk V
AU - Soheili A
AU - Sousa RARC
AU - Spurlock EE
AU - Stambolian D
AU - Taddele BW
AU - Tadesse EG
AU - Tahhan N
AU - Tareque MI
AU - Topouzis F
AU - Tran BX
AU - Travillian RS
AU - Tsilimbaris MK
AU - Varma R
AU - Virgili G
AU - Wang YX
AU - Wang N
AU - West SK
AU - Wong TY
AU - Zaidi Z
AU - Zewdie KA
AU - Jonas JB
AU - Vos T
AB - Background
To contribute to the WHO initiative, VISION 2020: The Right to Sight, an assessment of global vision impairment in 2020 and temporal change is needed. We aimed to extensively update estimates of global vision loss burden, presenting estimates for 2020, temporal change over three decades between 1990–2020, and forecasts for 2050.
Methods
We did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. Only studies with samples representative of the population and with clearly defined visual acuity testing protocols were included. We fitted hierarchical models to estimate 2020 prevalence (with 95% uncertainty intervals [UIs]) of mild vision impairment (presenting visual acuity ≥6/18 and <6/12), moderate and severe vision impairment (<6/18 to 3/60), and blindness (<3/60 or less than 10° visual field around central fixation); and vision impairment from uncorrected presbyopia (presenting near vision
Findings
In 2020, an estimated 43·3 million (95% UI 37·6–48·4) people were blind, of whom 23·9 million (55%; 20·8–26·8) were estimated to be female. We estimated 295 million (267–325) people to have moderate and severe vision impairment, of whom 163 million (55%; 147–179) were female; 258 million (233–285) to have mild vision impairment, of whom 142 million (55%; 128–157) were female; and 510 million (371–667) to have visual impairment from uncorrected presbyopia, of whom 280 million (55%; 205–365) were female. Globally, between 1990 and 2020, among adults aged 50 years or older, age-standardised prevalence of blindness decreased by 28·5% (–29·4 to −27·7) and prevalence of mild vision impairment decreased slightly (–0·3%, −0·8 to −0·2), whereas prevalence of moderate and severe vision impairment increased slightly (2·5%, 1·9 to 3·2; insufficient data were available to calculate this statistic for vision impairment from uncorrected presbyopia). In this period, the number of people who were blind increased by 50·6% (47·8 to 53·4) and the number with moderate and severe vision impairment increased by 91·7% (87·6 to 95·8). By 2050, we predict 61·0 million (52·9 to 69·3) people will be blind, 474 million (428 to 518) will have moderate and severe vision impairment, 360 million (322 to 400) will have mild vision impairment, and 866 million (629 to 1150) will have uncorrected presbyopia.
Interpretation
Age-adjusted prevalence of blindness has reduced over the past three decades, yet due to population growth, progress is not keeping pace with needs. We face enormous challenges in avoiding vision impairment as the global population grows and ages.
BT - The Lancet Global Health
DO - 10.1016/s2214-109x(20)30425-3
IS - 2
LA - eng
N2 - Background
To contribute to the WHO initiative, VISION 2020: The Right to Sight, an assessment of global vision impairment in 2020 and temporal change is needed. We aimed to extensively update estimates of global vision loss burden, presenting estimates for 2020, temporal change over three decades between 1990–2020, and forecasts for 2050.
Methods
We did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. Only studies with samples representative of the population and with clearly defined visual acuity testing protocols were included. We fitted hierarchical models to estimate 2020 prevalence (with 95% uncertainty intervals [UIs]) of mild vision impairment (presenting visual acuity ≥6/18 and <6/12), moderate and severe vision impairment (<6/18 to 3/60), and blindness (<3/60 or less than 10° visual field around central fixation); and vision impairment from uncorrected presbyopia (presenting near vision
Findings
In 2020, an estimated 43·3 million (95% UI 37·6–48·4) people were blind, of whom 23·9 million (55%; 20·8–26·8) were estimated to be female. We estimated 295 million (267–325) people to have moderate and severe vision impairment, of whom 163 million (55%; 147–179) were female; 258 million (233–285) to have mild vision impairment, of whom 142 million (55%; 128–157) were female; and 510 million (371–667) to have visual impairment from uncorrected presbyopia, of whom 280 million (55%; 205–365) were female. Globally, between 1990 and 2020, among adults aged 50 years or older, age-standardised prevalence of blindness decreased by 28·5% (–29·4 to −27·7) and prevalence of mild vision impairment decreased slightly (–0·3%, −0·8 to −0·2), whereas prevalence of moderate and severe vision impairment increased slightly (2·5%, 1·9 to 3·2; insufficient data were available to calculate this statistic for vision impairment from uncorrected presbyopia). In this period, the number of people who were blind increased by 50·6% (47·8 to 53·4) and the number with moderate and severe vision impairment increased by 91·7% (87·6 to 95·8). By 2050, we predict 61·0 million (52·9 to 69·3) people will be blind, 474 million (428 to 518) will have moderate and severe vision impairment, 360 million (322 to 400) will have mild vision impairment, and 866 million (629 to 1150) will have uncorrected presbyopia.
Interpretation
Age-adjusted prevalence of blindness has reduced over the past three decades, yet due to population growth, progress is not keeping pace with needs. We face enormous challenges in avoiding vision impairment as the global population grows and ages.
PB - Elsevier BV
PY - 2021
SP - e130
EP - e143
T2 - The Lancet Global Health
TI - Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study
UR - https://www.thelancet.com/action/showPdf?pii=S2214-109X%2820%2930425-3
VL - 9
SN - 2214-109X
ER -